SCHEMBL5864800

SCHEMBL5864800

N#Cc1cccc(C=Cc2ccc(Cl)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
KDM4E B2RXH2 5/20 0.50
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
DHFR P00374 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GRM4 Q14833 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PKM P14618 2/20 0.40
HPGD P15428 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
GRM5 P41594 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864794 1.00 NPC1 (0.50) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL4712459 0.85 GRM4 (0.56) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL4712457 0.85 GRM4 (0.56) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5865152 0.84 RELA (0.45) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5865155 0.84 RELA (0.45) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5864968 0.84 KDM4E (0.47) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5865233 0.84 GRM4 (0.50) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5865235 0.84 GRM4 (0.50) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5864973 0.84 KDM4E (0.47) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL5864985 0.83 CHAT (0.39) ALDH1A1MAPTTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1837195-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2006-09-27 CN disclosed
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
US-6951875-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
CN-1578662-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2005-02-09 CN disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. 2003-07-31 US disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C NPC1 646/4885RAB9A 2741/4885KDM4E 1020/4885
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C NPC1 646/4885RAB9A 2741/4885KDM4E 1020/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C NPC1 804/4885RAB9A 2959/4885KDM4E 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.